Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.

Molecular oncology - 1 Sept 2020

Thomsen Emil Aagaard, Rovsing Anne Bruun, Anderson Mads Valdemar, Due Hanne, Huang Jinrong, Luo Yonglun, Dybkaer Karen, Mikkelsen Jacob Giehm

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is characterized by extensive genetic heterogeneity, and this results in unpredictable responses to the current treatment, R-CHOP, which consists of a cancer drug combination supplemented with the humanized CD20-targeting monoclonal antibody rituximab. Despite improvements in the patient response rate through rituximab addition to the treatment plan, up to 40% of DLBCL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antigens, CD20

Share to CRISPR-Cas Systems

Share to Germinal Center

Share to Lymphoma, Large B-Cell, Diffuse

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 32585766
DOI: 10.1002/1878-0261.12753
PMCID: PMC7463323

Genes

BCR
BLNK
BTK
MS4A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.PMID 32585766Read ↗

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.Semantic proximity Read ↗

DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.Semantic proximity Read ↗

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphomaSemantic proximity Read ↗

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphomaSemantic proximity Read ↗

Genetic Events Inhibiting Apoptosis in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.Semantic proximity Read ↗

Genome-wide discovery of somatic coding and regulatory variants in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase InhibitionSemantic proximity Read ↗

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomasSemantic proximity Read ↗

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.